Quantgene | June 08, 2021
Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics.
"Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of human life is dependent on the advancement of precision genomics, and we are excited to open a new chapter in genomic testing and less invasive cancer screening."
DEEPGENTM reduced error rates on Illumina NovaSeq platforms hundreds of times by integrating new chemistry with large-scale cloud processing, mathematically enhanced error reduction, and statistically optimized genomic mapping, signaling an innovative approach ahead for cancer testing. Quantgene's latest innovation is a significant step forward in evidence-based healthcare and precision medicine.
Quantgene's DEEPGEN technology was thoroughly investigated in its peer-reviewed publication, which included a series of technical validations. According to the publication, the system detects somatic variations in DNA fragments with an accuracy of more than 1 in 1000 fragments, with high repeatability and very low false-positive results. This degree of accuracy has previously only been proven in a peer-reviewed setting for systems that examined a small number of genomic regions. DEEPGEN's technology covers around 70,000 locations and includes a wide range of FDA-approved cancer targets.
The results of Quantgene represent a significant advance in the identification of cancer signals in the blood using liquid biopsy and next-generation sequencing technology. Liquid biopsy can be a less invasive and more accurate method of diagnosing different forms of cancer. In oncology, it may also be used to aid physicians in early cancer detection, companion diagnostics, and identifying minimum residual disease.
"This is a crucial step forward in precision medicine. Quantgene provides the industry with a more powerful tool to diagnose cancer and other serious diseases earlier than ever before by achieving single-molecule sequencing precision ", said Jo Bhakdi, CEO of Quantgene.
Quantgene has emerged as a technical leader in single-molecule precision sequencing over the last six years. To better protect patients from cancer, the company combines deep genomic, cloud, and AI technologies with innovative preventative medicine solutions. Its objective is to increase the healthy human lifespan by ten years within the next ten years.
Medical Xpress | December 26, 2019
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing. The feat, reported in the scientific journal Nature Biotechnology, offers gene therapy designers what may be the first viable technique for adjusting the activity levels of their therapeutic genes. The lack of such a basic safety feature has helped limit the development of gene therapy, which otherwise holds promise for addressing genetically based conditions. The scientists' technique appears to solve a major safety issue and may lead to more use of the strategy.
Medical Xpress | December 23, 2019
Researchers at The University of Western Australia, Harry Perkins Institute of Medical Research and Curtin University have made a fundamental discovery about of the regulation of genes in mitochondria, providing a new insight into potential drug targets for diseases that involve energy loss. The research, published today in Science Advances, was led by UWA's Professor Aleksandra Filipovska, Head of Mitochondrial Medicine and Biology, in collaboration with Curtin University's Professor Oliver Rackham, Head of Synthetic Biology and Drug Discovery; and UWA's School of Human Sciences Professor Livia Hool, and their Ph.D. students Danielle Rudler and Laetitia Hughes.